OnKure Ther­a­peu­tics nabs $60M as HDAC in­hibitor awaits sol­id-tu­mor read­outs

OnKure Ther­a­peu­tics has lined up $60 mil­lion in a new pri­vate fund­ing round, adding to the Boul­der, CO, biotech’s bank ac­count as it works through a Phase II tri­al.

The start­up is at­tempt­ing to cre­ate an in­hibitor of hi­s­tone deacety­lases, or HDACs, which are DNA-ma­nip­u­lat­ing en­zymes that al­ter how genes get ex­pressed. They’ve been a can­cer tar­get for decades, with about half a dozen FDA ap­provals for the class, but treat­ment nods so far have fo­cused on blood can­cers. That in­cludes the drugs Zolin­za, Is­to­dax, Beleo­daq, Ep­i­daza and Fary­dak.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER